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Abstract
Background: Most cancers express elevated protease levels which contribute to certain aspects
of tumor behavior such as growth, metastatic spread, and angiogenesis. Elevation of the cathepsins
of the cysteine protease family correlates with increased invasion of tumor cells. Cysteine
proteases such as cathepsins B, H and L type participate in tumor cell invasion as extracellular
proteases, yet are enzymes whose exact roles in metastasis are still being elucidated.
Methods:  We have examined the role of cathepsin L in highly metastatic B16F10 murine
melanoma cells through genetic antisense constructs of cathepsin L. The effects of cathepsin L
antisense were examined for melanoma cell proliferation, invasion, migration and adhesion.
Results: Antisense expression of cathepsin L, while decreasing enzyme activity in cell lysates, did
not influence cell proliferation. Cathepsin L contributed to melanoma cell invasion and also
augmented melanoma cell migration. Further, we demonstrated the adhesion of cathepsin L down-
regulated clones was unaltered to fibronectin, laminin, and collagen. Finally, the inhibition of
melanoma cell migration via down-regulation of cathepsin L appears to be independent of cystatin
C expression.
Conclusion: This study shows that cathepsin L facilitates high metastatic B16 melanoma cell
invasion and migration. The mechanism of migration inhibition by decreased cathepsin L is
independent of cystatin C levels. Since metastasis depends upon both the invasiveness and
migration of tumor cells, cathepsin L may be a therapeutic target of strong clinical interest.
Background
When melanoma progresses to a metastatic form, it is
associated with a poor prognosis. Metastatic melanoma is
seldom cured with current chemotherapeutic or other reg-
imens. New therapeutic strategies designed to deal with
the metastatic spread of melanoma will require investiga-
tion of new molecular targets. Metastatic tumor cells
invade host tissues through a series of steps, one or more
of which requires proteolytic enzymes for invasion [1].
The cysteine proteases of the papain family, particularly
cathepsins B, H and L, have been closely linked to tumor
progression in multiple tumor types [2-4]. The prognosis
of several major cancers has also been correlated with
tumor cysteine proteinase expression in several recent
studies [5,6]. Although the specific roles of cysteine pro-
teases in metastasis remain unclear, undoubtedly these
proteases participate in invasive degradation of extracellu-
lar matrix components in conjunction with other classes
of proteases [7]. Modulation of tumor cell and host cell
interactions by cathepsins is another important area of
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which little is known. Additionally, activation of other
cancer cell related proteases occurs by action of cysteine
proteases and contributes to tumor invasion [8].
Cathepsin L, although less well studied than cathepsin B,
has been linked to tumor invasion and metastasis [9,10].
Over-expression of cathepsin L was linked to metastasis
following ras transformation of NIH/3T3 cells [11]. More
recently, non-metastatic melanoma cells were converted
to metastatic cells by over-expression of cathepsin L [12].
Membrane association of cathepsin L in human and
murine melanoma cells suggests extra-lysosomal func-
tions of cathepsin L in metastasis [13]. Cathepsin L has
additional complexity in that control of activity occurs
through regulatory mechanisms which include pro-form
processing of the enzyme and inhibition by proteins
termed cystatins [14]. We have shown cystatin C, a potent
cathepsin L inhibitor, blocks motility and invasion of
melanoma cells [15,16]. The mechanism of cystatin
blockade of melanoma invasion is not yet known. Cathe-
psin L could possibly modulate cystatin levels to influence
invasion and this question prompted us to study cathep-
sin L further.
Although cathepsin L has been shown to contribute to
melanoma cell invasion, other properties of melanoma
cells such as migration, adhesion and proliferation have
not been well studied. Previous studies have used syn-
thetic cysteine protease inhibitors to study tumor-associ-
ated cathepsins which can lack specificity for cathepsin
subtypes. Also, synthetic cysteine protease inhibitors can
have toxic or other unwanted effects that limit conclu-
sions in cellular studies. To circumvent problems with
inhibitors, we have produced anti-sense clones to cathep-
sin L in B16 melanoma cells. In this study we have exam-
ined the effect of cathepsin L down-regulation on the in
vitro  behavior of highly metastatic B16F10 melanoma
cells. Our results show cathepsin L makes a major contri-
bution to melanoma cell invasion, particularly through
cell migratory influences. Cell proliferation, adhesion,
and cystatin C levels were not influenced by cathepsin L
down-regulation.
Results
Initial characterization of cathepsin L antisense cathepsin 
L clones
The region of cathepsin L gene chosen for antisense con-
struction was a 325 bp sequence contained within exon 3.
We chose this sequence because it is near the 5' end of the
cathepsin L message, as 5' sequences often make better
antisense constructs [17]. We checked for DNA sequence
similarities between the cloned cathepsin L sequence and
other cysteine proteases through Genbank and found no
matches. The identities of several sense and antisense
plasmid constructs were confirmed by DNA sequence
analysis. Cathepsin L antisense (and sense) expression
plasmid pcDNA-3 constructs were transfected into highly
metastatic B16F10 cells. The relative cathepsin L message
level for a number of clones was determined by RT-PCR
(Fig. 1A). Seven putative cathepsin L antisense clones
showed significant reduction (50–80%) of cathepsin L
message. Two putative clones did not (AS-2 and AS-9). In
our study two clones (PC2 and AS-2) showed differences
which reached P < .05 level but were much less than the
clear differences for most antisense clones. We chose sev-
eral clones with clearly reduced message for further study.
Assay of cathepsin L activity
Relative cathepsin L enzyme activities were determined
for several clonal cell lysates by fluorometric measure-
ment of stopped assays. Since the protease substrate used
in these assays (Z-Phe-Arg-AMC) measures primarily
cysteine protease activity under the conditions used, the
cathepsin L selective inhibitor Z-Phe-PheCHN2 was used
in parallel assays so that cathepsin L activity could be
determined by difference (Fig. 1B). Cathepsin L activities
were found to be reduced by about 80% compared to con-
trol activities. We also tested purified cathepsin B with Z-
Phe-PheCHN2 at the levels used in cell lysate assays and
found no inhibition (data not shown). Most of the non-
cathepsin L enzyme activity likely reflects cathepsin B
activity that did not vary between clone types (antisense
versus sense).
Growth
We also compared the in vitro growth of a cathepsin L anti-
sense clone to B16F10 parental cells under standard cul-
ture conditions (Fig. 1C). No significant difference was
seen in the growth rate of an antisense clone compared to
a control clone over a two-day period.
Western blot analysis of cathepsin L
To determine if the level of cathepsin L protein correlated
with relative cathepsin L message levels determined by RT-
PCR, we performed a Western blot analysis of several B16
melanoma clones. The cathepsin L protein level was sig-
nificantly reduced in two select cathepsin L antisense
clones relative to two control clones (Fig 1D). Based on
the Western blot analysis, less than half of the cathepsin L
protein is present in the antisense clones tested.
Invasion of cathepsin L antisense clones
The invasion of tissue stromal and extracellular matrices is
a hallmark feature of metastasis. The relative invasion of
basement membrane by metastatic cells often correlates
with level of proteolytic enzyme expression. A common
assay used to measure relative invasiveness of cancer cells
is with a Boyden chamber type assay with Matrigel coated
filters. We found that the invasion of cathepsin L anti-
sense clones was reduced by about 70% compared to con-
trol clones in a Boyden chamber invasion assay after 24
hours (Fig. 2A).
Migration of cathepsin L antisense clones
Cell migration is another key feature underlying meta-
static ability. First we looked at migration of several cathe-Cancer Cell International 2007, 7:8 http://www.cancerci.com/content/7/1/8
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Characterization of cathepsin L antisense clones Figure 1
Characterization of cathepsin L antisense clones. (A) RT-PCR of cathepsin L message levels. Semi-quantitative RT-PCR 
was used to determine average relative cathepsin L message levels (performed in triplicate). Actin was used as an internal con-
trol and the relative product band densities were calculated based on measured pixels per band on scanned images with Image 
J software. Controls are B16F10 and PC2 (empty vector); AS1–9 are putative antisense clones. S3 is a sense clone. The differ-
ence between cathepsin L message levels for control and antisense clones (except AS-2 and AS-9, *P < 0.05) were significant by 
Student t-test (** P < 0.001). (B) Growth rates of cathepsin L clones. Cells were seeded in 96-well culture dishes at 1 × 103 
per well. At the times indicated, MTT was added (50 ul of a 5 mg/ml solution) for incubation at 37°C for 4 hours. Media was 
then removed and reaction product solubilized in 100 μl DMSO for 2 hours at room temperature. Absorbances were read at 
A570 nm wavelength. Clones were run in triplicate wells in triplicate experiments. No significant difference was noted between 
the clones analyzed by Student t-test. (C) Cathepsin L activity of sense and antisense cathepsin L clones. Clones S1 and S3 are 
sense clones. Clones AS3, AS4, AS5, AS7, and AS8 are antisense clones. Cell extracts were prepared by lysis with incubated 
with Z-Phe-Arg-AMC for 30 minutes, with or without cathepsin L inhibitor in triplicate. The proteolytic activity was expressed 
in units (1 U = 1 μmol product per minute). ANOVA analysis showed significant differences between sense and antisense 
cathepsin L activities (* P < 0.01). (D) Western blot analysis of cathepsin L. Controls B16F10 and PC2 (pcDNA-3 vector trans-
fected) were compared to antisense clones AS3 and AS5 for cathepsin L levels in cell extracts by Western blot analysis. West-
ern blot detection was with ECL (Amersham) reagents.Cancer Cell International 2007, 7:8 http://www.cancerci.com/content/7/1/8
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In vitro behavior of cathepsin L antisense clones Figure 2
In vitro behavior of cathepsin L antisense clones. (A) Invasion assay of cathepsin L sense and antisense clones. Data rep-
resents the number of cells per filter (counted with a 40X objective) that had crossed a Matrigel barrier during 24 hours incu-
bation at 37°C. Triplicate wells were run in triplicate. Analysis of variance (ANOVA) showed there was a significant difference 
between antisense clones (AS) and sense clones (S) (* P < 0.001). (B) Migration of cathepsin L sense and antisense clones in 
Boyden chamber. Data is as for invasion, but with no Matrigel barrier. Migration difference was significant by Student t test (*P 
< .05). (C) Radial migration with sedimentation chamber. Cells (2 × 103 cells per well) were plated on glass slide wells in tripli-
cate using a cell sedimentation chamber. Chemokinetic bFGF (Sigma, 25 ng/ml) was used in these experiments. Cell colony 
diameters were imaged from 10X objective microscopic views. Data represent the average differences in cell colony diameter 
(mm) following 24-hour incubation on laminin-coated wells. Experiments were conducted in triplicate, and a significant differ-
ence was found between control and antisense clones by Student t-test analysis (*P < 0.01). (D) Morphological appearance of 
typical clones with light microscopy. Cells were plated on glass coverslips overnight and then images were taken using a 10 X 
objective. A) Control PC2 cells B) Cathepsin L antisense (AS5) cells. (E) Adhesion of cathepsin L antisense clones to extracel-
lular matrix proteins. Plastic 96-well plates were coated with extracellular matrix proteins. Fibronectin and laminin were used 
to pre-coat wells with 10 μg/ml. Collagen I was pre-coated at 100 μg/ml. Cells (2 × 104 per well) were added prior to incuba-
tion for specified times. Wells were washed with PBS twice, cells fixed with 4% paraformaldehyde, and stained with crystal vio-
let prior to reading absorbances (A595) of Triton X-100 (1% in PBS) lysed cells. Triplicate wells were run in triplicate and 
averaged. No significant difference was noted by Student's t test.Cancer Cell International 2007, 7:8 http://www.cancerci.com/content/7/1/8
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psin L anti-sense clones with Boyden chamber assays (Fig.
2B). Cell migration of the clones paralleled the general CL
message level measured (Fig. 1A). Antisense clones from
the group with low CL message level (and relative migra-
tion) were focused upon for further studies. The cell
migration of cathepsin L antisense clones compared to
control clones was also measured with a radial migration
assay (Fig. 2C) [18]. We chose this assay so that any barri-
ers to 2d cell migration would be eliminated. In this assay
cells were seeded onto laminin-coated surfaces. We found
that antisense cathepsin L clones showed a 60–80%
decrease in cell migration measured in a radial migration
assay over 24 hours. During the course of this assay some
proliferation of cells would occur. Our results on cell pro-
liferation, however, show that observed differences in 24
hour radii between antisense cell colonies and control cell
colonies are not due to proliferative differences.
Adhesion of antisense clones
Cellular adhesion to extracellular matrices is an important
determinate for cell migration. The appearance of cathep-
sin L antisense clones was checked for morphological dif-
ferences that might account for migratory differences.
After overnight culture of newly seeded cells, cathepsin L
antisense clones appeared slightly more rounded (less
spindle shaped) (Fig. 2D). This morphological difference
may relate to reduced actin cytoskeletal remodeling
expected of less migratory cells. Since adhesion of cells to
extracellular matrices can impact cell migration, we tested
random cathepsin L clones for adhesion to several differ-
ent extracellular matrix proteins (Fig. 2E). Our results
showed no significant difference in the ability of
melanoma cathepsin L antisense clones to adhere to
fibronectin, laminin, or collagen over a 1–2 hour period.
We conclude cell adhesion of antisense clones is not a fac-
tor to account for the major differences we find in cell
migration and invasion.
Western analysis of cystatin C in cell supernatants
Extracellular cystatin levels were found not to change
when cathepsin L down-regulated clones were compared
to control clones (Fig. 3). This result suggests cathepsin L
does not regulate the level of cystatin production to influ-
ence cell migration and invasion indirectly through cysta-
tin levels.
Real-time PCR analysis of cystatin C
Real-time PCR was carried out for cystatin message levels
in parental B16, vector control-transfected and two cathe-
psin L antisense clones. We found cystatin C message lev-
els were similar in cathepsin L antisense clones compared
to B16F10 or empty plasmid transfected controls (Table
1).
Discussion
In this work we have examined the in vitro contribution of
cathepsin L to the behavior of high-metastatic B16 F10
melanoma cells. Based on earlier work in the literature, we
hypothesized cathepsin L would make a major contribu-
tion to B16 melanoma invasion [19,20]. To test this hypo-
thesis we transfected B16F10 melanoma cells with
cathepsin L antisense and sense RNA expression plasmid
constructs. Our cathepsin L antisense expression clones
produced effective, stable, down-regulation of cathepsin L
message level, protein, and enzyme activity. Both
melanoma cell migration and invasion were found to be
inhibited in cathepsin L antisense clones. Adhesive and
proliferative differences between cathepsin L antisense
and sense clones were not detected. Also, no influence of
cathepsin L down-regulation on cystatin C mRNA produc-
tion or secretion was found. We take these results to mean
cathepsin L has direct effects on the cell motility and con-
tributes its proteolytic action to the active invasion of
melanoma cells.
Tumor invasion of host tissues requires multiple pro-
teases, among which the catheptic cysteine proteases are
typically elevated. Cathepsins B, H, and L have been
shown to be elevated in many cancer types, both intracel-
lularly as well as extracellularly [21,22]. It is known B16
melanoma cells exhibit elevated cathepsins B, H, and L
levels due to increased transcription [23]. Earlier work
established cathepsins B and L contribute to melanoma
cell invasion in vitro [24].
Other properties of melanoma cells potentially influ-
enced by cathepsins, such as adhesion, migration, and
proliferation have received less study. We have addressed
these parameters in this highly metastatic melanoma cell
line. It would be expected that cell invasion might
Table 1: 
Clone Ct ratio (cystatin C/actin)
B16F10 0.94
PC2 0.92
AS3 0.97
AS5 1.00
Expression of cystatin C by cathepsin L antisense clones Figure 3
Expression of cystatin C by cathepsin L antisense 
clones. Western blot analysis of cystatin C in spent media. A 
representative Western blot of three independent experi-
ments is shown.Cancer Cell International 2007, 7:8 http://www.cancerci.com/content/7/1/8
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decrease due to reduced extracellular cathepsin L since
extracellular matrix degradation by cathepsin L is known
to occur. Less clear, however, is how cysteine proteases
might be involved in cell migration. One way cysteine
proteases might play a role in tumor cell migration is
through activation of other proteases known to play a
direct role in tumor cell migration [8]. Direct proof of this
mechanism in vivo is lacking in the literature. A second
clue to cathepsin involvement in tumor cell migration
comes from a study of cathepsin B knockdown in glioma
cells [25]. Inhibition of glioma cell migration with cathe-
psin B down-regulation correlated with altered cofilin
phosphorylation. This is the first linkage of cathepsins
and cytoskeletal changes involved in cell migration.
The relative importance of cysteine proteinases to tumor
cell invasion has been addressed recently with different
strategies. One study used antisense oligonucleotides to
cathepsin L and demonstrated decreased migration and in
vitro invasion of human osteosarcoma cells [26]. Differ-
ences exist, however, for the roles of cathepsin L in differ-
ent cancer cell types. For example, antisense constructs to
cathepsin L in human glioma cells have been shown to
block invasion but not migration [19]. Intracellular
expression of an antibody to cathepsin L has also been
shown to block cathepsin L secretion and dramatically
inhibit melanoma metastasis [27]. Secreted cathepsin L in
this study was shown to be involved in both invasion and
angiogenesis although migration was not measured
directly.
One possible avenue towards mechanistic details con-
cerns the use of synthetic cysteine protease inhibitors or
cystatins. Most invasive tumors express elevated cysteine
protease levels and at least half display decreased cysteine
protease inhibitor levels relative to untransformed tissues
[28]. Cysteine protease inhibitors, such as the cystatins,
decrease tumor cell migration when applied exogenously,
although the mechanism of migration inhibition is
unclear [29]. We previously found cystatin C over-expres-
sion decreased B16 melanoma cell migration [30]. If
cystatin C is over-expressed, one would expect decreased
extracellular cathepsin L activity to correlate with a less
migratory cell phenotype. Our cystatin C over-expression
clones were found to be deficient for cystatin secretion
and therefore deemed a poor model for examining extra-
cellular cathepsin L regulation [16].
Recently, cathepsin L has been found to modulate gene
transcription in NIH/3T3 cells by proteolytically activat-
ing nuclear transcription factors and suggests how pro-
tease expression might influence the expression of other
genes [31]. The intriguing possibility that cathepsin L
might be inducing cell migratory factors in melanoma
needs to be tested with gene array analysis. Genetic sup-
port for this reasoning comes from cathepsin L knockout
mice which show reduced cell migration in podocytes
[32].
New therapeutic strategies that target cysteine proteases of
the papain family may be able to interfere with metastatic
spread of certain cancers. How central a role cysteine pro-
teases play in cancer cell invasion depends, in part, upon
the redundancy of other classes of proteolytic enzymes
involved in invasion. Non-proteolytic functions of the
cathepsins might also contribute to tumor cell invasion as
has been found for urokinase plasminogen activator [33].
In conclusion, we have shown that cathepsin L antisense
clones did not display altered cell proliferation or adhe-
sion to different protein substrates. Cathepsin L down-
regulation also does not appear to be linked to expression
of the cysteine protease inhibitor cystatin C. Cathepsin L
does however make a significant contribution to B16F10
melanoma cell invasion, particularly through cell migra-
tion. Cathepsin L should therefore be an anti-metastatic
therapeutic target of future interest.
Methods
Cell culture
The highly metastatic cell line B16F10 was a gift from Dr.
Isaiah Fidler (MD Anderson Cancer Center, Houston,
Texas, USA). Cells were cultured in complete media:
RPMI-1640 media (Sigma) supplemented with 10% fetal
bovine serum (FBS, Sigma) and antibiotics (100 units/ml
penicillin, 0.1 mg/ml streptomycin, 0.25 mg/ml fungi-
zone)(Bio-Whittaker) at 5% CO2, 37°C in humidified cell
culture chambers.
Cathepsin L antisense DNA clones
A 325 base pair fragment corresponding to a portion of
murine cathepsin L exon 3 DNA sequence was amplified
from total B16F10 RNA by an RT-PCR reaction [34]. The
primers used for amplification of cathepsin L exon 3 DNA
sequence were left primer (5'-AGTCCACCGCACAGAA-
GACTGTA-3') and right primer (5'-CCGGTCTTAAGGAA-
CATCTGTC-3'). The PCR-amplified cathepsin L DNA
fragment was cloned as a blunt-ended fragment into the
Sma I site of pcDNA-3 plasmid (Invitrogen) in both sense
and antisense directions. Cloned cathepsin L DNA frag-
ments were confirmed by DNA sequence analysis carried
out at the University of Chicago Cancer Center. Plasmid
DNA from vector, sense, and antisense clones were puri-
fied and transfected into B16F10 cells by the calcium
phosphate method [35]. After 2–3 weeks growth in com-
plete media plus Geneticin (1 mg/ml (Sigma)), well sepa-
rated cell colonies were retrieved from cloning rings
following brief trypsin treatment for further analysis.
Quantitation of relative cathepsin L mRNA levels in
selected clones was by PCR amplification of reverse tran-
scription products. Total RNA was isolated with Tri-Rea-Cancer Cell International 2007, 7:8 http://www.cancerci.com/content/7/1/8
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gent (Sigma) and treated with DNase I (1 unit/μg RNA)
for 20 minutes prior to reverse transcription. Reverse tran-
scription of 1 μg of total RNA was carried out with an
enhanced AMV reverse transcriptase (Sigma) reaction
with right cathepsin L primer (100 ng/reaction). Exon 3 of
murine cathepsin L was then amplified for 30 cycles from
5 μl reverse transcription reaction product. An internal
control of β-actin (0.5 μl of an actin RT-PCR reaction pre-
pared from 1 μg B16 F10 melanoma RNA) was included
in the PCR reaction to normalize the amount of cathepsin
L specific products. Mouse actin primers used were AM1
(5'-ATGGGTCAGAAGGACTCCTAT-3') and AM2 (5'-
AAGGTCTCAAACATGATCTGGG-3') [36]. Digital photos
of amplified bands on agarose gels were scanned with a
CCD camera and quantified with Scion Image Beta 4.0.2
program. The ratio of cathepsin L PCR product to actin
PCR product in terms of pixels per band was calculated for
each clone.
Assay of cathepsin L activity
An enzyme assay for cathepsin L activity was used with
slight modification from Kirshke et al. [7]. A stopped
assay for cysteine protease activity (30 minute incubation)
was carried out with Z-Phe-Arg-AMC (14 μM) (Enzyme
Systems, Inc.) as substrate for fluorometric measure-
ments. In these assays, one unit of enzyme activity equals
1 μmole of substrate hydrolyzed per minute. The specific
cathepsin L inhibitor Z-Phe-Phe-N2 (Enzyme Systems,
Inc.) was used at 4 μM in some assays as 0.4 μM inhibitor
failed to totally inhibit cathepsin L in our assays. Cathep-
sin B activity was not inhibited by 4 μM inhibitor concen-
tration  in vitro (data not shown). Protein assays were
carried out with a modified Lowry assay [37].
Invasion and migration assays
Melanoma cell invasion was measured with modified
Boyden chambers (Nucleopore) as described previously
[30]. Briefly, polycarbonate filters with 8 μm pores
(Nucleopore) were etched with 10% acetic acid solution
overnight at 4°C. Membranes were then coated with gela-
tin solution (0.1%) for 4 hours at room temperature. Fil-
ters were then washed twice in PBS and air-dried in a
laminar flow hood. Filters were next coated with Matrigel
(BD Biosciences) (65 μg/filter) and dried before use. Cell
growth media plus basic fibroblast growth factor (bFGF)
(25 ng/ml) filled the lower chamber and the top chamber
received 200 ul media plus 2 × 104 cells. After 24 hours at
37°C, filters were removed and cells on the bottom sur-
face were fixed for 10 minutes in methanol. Cells were
permeabilized for 2 minutes in 0.1% Triton X-100-PBS
solution before staining in Harris hematoxylin solution
(Sigma) for 10 minutes. After a 2-minute rinse in tap
water, filters were mounted directly on glass slides for cell
counting with an inverted microscope using a 40X objec-
tive. A migration assay was also performed by this same
method with filters pre-coated with collagen I (Sigma) at
10  μg/ml at 4°C overnight, but no Matrigel coating.
Migration of cells was for 10 hours in complete media
with 25 ng/ml bFGF in the lower well.
Radial migration assay
Melanoma cell migration was measured in a radial migra-
tion assay [18]. Ten well slides and sedimentation mani-
fold were obtained from CSM Inc, Phoenix, AZ. Wells
were coated with laminin (10 μg/ml in phosphate buff-
ered saline (PBS) at 100 μl per well) for 1 hour at 37°C.
The wells were then washed twice with PBS and air-dried.
Cells were seeded through the sedimentation manifold at
2 × 103 cells per well onto glass slides containing complete
cell growth media plus basic fibroblast growth factor
(bFGF)(Sigma) at 25 ng/ml. All migration and invasion
assays include bFGF as a chemokinetic factor to maximize
cell migration rates. Incubation of the seeded cells for 4
hours allowed the cells to establish a 1 mm diameter col-
ony of attached cells per well. An initial image was taken
of the well field and then again after 24 hours to permit
cell migration. Migration results are the change in the
radius of the cell population over a 24-hour period. In this
assay, cathepsin L antisense clones were always run on the
same slides as sense clones to minimize variability. Meas-
urements were taken with a 10X objective on an inverted
microscope (Lomo Invertoscope) and digitized with a
camera (Senetech 620). Image analysis was performed
with Image J software.
Cell adhesion assay
Fibronectin (Sigma) and laminin (Sigma) were diluted in
PBS to 10 μg/ml, and 100 μl solutions were used to coat
96 well plates for 1 hour at 37°C. Excess solution was
removed from wells followed by a wash with PBS. Wells
were used immediately for adhesion assays. Collagen I
(100 μg/ml in PBS) (Upstate) was used to coat wells under
the same conditions. Cells were removed from near con-
fluent dishes with 0.02% trypsin, and the trypsin was neu-
tralized with an equal volume of complete media. Cells
were then diluted in serum-free DMEM plus 0.1% BSA to
a final concentration of 2 × 105 cells per ml. Suspended
cells (2 × 104) were added to each well for either 30 or 60
minutes incubation at 37°C (120–240 minutes for colla-
gen I) before unattached cells were removed by washing
twice with PBS. Cells were then fixed with 2% paraformal-
dehyde in PBS for 10 minutes at room temperature. After
washing the wells with PBS, the cells were stained with
crystal violet (0.1%) for 20 minutes at room temperature.
Wells were then washed 3X with PBS and the cells lysed in
PBS containing 1% Triton X-100 before well absorbances
were read at A595.Cancer Cell International 2007, 7:8 http://www.cancerci.com/content/7/1/8
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Western blots
Cellular protein was extracted from near confluent 35 mm
culture dishes with lysis buffer (20 mM Tris, pH 7.5, 150
mM NaCl, 1 mM MgCl2, 2 mM EGTA, 10% glycerol,
0.15% SDS, 1% deoxycholate, 1% Triton X-100, 1% anti-
protease cocktail (Sigma)). When cell lysates were ana-
lyzed, 50 μg total protein was loaded per sample. Cathep-
sin L mouse monoclonal IgG (1:1000) (Alexis) and actin
rabbit polyclonal IgG (1:1000) (Santa Cruz) were used for
Westerns. Immunoreactive bands were detected with
horse radish peroxidase (HRP) linked anti-rabbit IgG
(Santa Cruz Biotechnology) by enhanced chemilumines-
cence (ECL, Amersham Life Sciences). For cystatin C anal-
ysis in culture supernatants a rabbit polyclonal anti-
cystatin C (1:1000) (Upstate) was used. Several
melanoma cell clones were grown to near confluence and
then switched to serum-free DMEM media plus 25 mM
HEPES buffer for 24 hours. Spent media was then dia-
lyzed against 1 mM HEPES, pH 8 overnight before lyophi-
lization of the samples 10 fold. The loaded sample
volumes were normalized to lysed cell protein prior to
Western blot analysis.
Quantitation of cystatin mRNA expression
The level of cystatin C mRNA expression was determined
by quantitative real-time PCR analysis. Total RNA was first
isolated by Tri-reagent (Sigma) and further purified over
RNeasy minicolumns following DNase treatment as per
manufacturer's instructions (Qiagen). Primer sets for
murine cystatin C were obtained from Superarray and
used for reverse transcription reactions (1 μg total RNA/
reaction) with Reaction Ready first-strand cDNA synthesis
kit (Superarray). Real-time quantitation was carried out
for each mRNA relative to actin message with a SYBR
green assay on an iCycler detection PCR system (Bio-rad).
A dilution of 1:100 of cDNA was used for actin PCR tem-
plate. We expressed the cystatin message level as a ratio of
Ct values for cystatin relative to control actin Ct values.
The Ct values were averages from triplicate PCR reactions
for each sample.
Abbreviations
bp, base pairs; BSA, bovine serum albumin; CL, cathepsin
L; DMSO, dimethylsulfoxide; ECL, enhanced chemilumi-
nescence; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-2H-
tetrazolium bromide; PBS, phosphate buffered saline, cal-
cium free.
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